1 Min Read
May 10 (Reuters) - Loxo Oncology Inc:
* Loxo Oncology announces enrollment of first patient in phase 1 clinical trial for highly selective ret inhibitor, loxo-292 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.